`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`SLAYBACK PHARMA LLC,
`Petitioner
`
`v.
`
`SUMITOMO DAINIPPON PHARMA CO., LTD.,
`Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2020-01053
`Patent No. 9,815,827
`
`
`
`
`
`
`
`
`
`
`
`
`
`PATENT OWNER’S MOTION TO SEAL UNDER 37 CFR § 42.54
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`
`I. Introduction
`
`Pursuant to 37 CFR § 42.54, Patent Owner, Sumitomo Dainippon Pharma
`
`Co., Ltd, respectfully submits this Motion to Seal Exhibits 2058-2060, 2069, 2074-
`
`2076, 2078, 2080, 2082-2083, 2089-2090, 2092-2095, 2131, 2132, and 2138, as
`
`well as its Patent Owner Response. In the case of Ex. 2131 and its Patent Owner
`
`Response, Patent Owner submits herewith non-confidential (redacted versions).
`
`Below, Patent Owner explains that Good Cause exists for placing these exhibits
`
`and the Patent Owner Response under seal.
`
`II. Applicable Legal Principles for Sealing Confidential Information
`
`There is a strong public policy for making all information filed in a quasi-
`
`judicial administrative proceeding open to the public, especially in an inter partes
`
`review which determines the patentability of claims in a patent and therefore
`
`affects the rights of the public. St. Jude Medical, Cardiology Division, Inc. v.
`
`Volcano Corp., IPR2013-00258, Decision to Revised Motion to Seal 37 C.F.R. §§
`
`42.14 and 42.54, Paper 28 at 2. Under 35 U.S.C. § 316(a)(1), the default rule is
`
`that all papers filed in an inter partes review are open and available for access by
`
`the public; and a party may file a concurrent motion to seal and the information at
`
`issue is sealed pending the outcome of the motion. Id.
`
`It is, however, only “confidential information” that is protected from
`
`disclosure. 35 U.S.C. § 316(a)(7) (“The Director shall prescribe regulations -- …
`
`1
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`providing for protective orders governing the exchange and submission of
`
`confidential information”). Id. In that regard, the Office Patent Trial Practice
`
`Guide, 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012), provides:
`
`The rules aim to strike a balance between the public’s interest in
`maintaining a complete and understandable file history and the
`parties’ interest in protecting truly sensitive information.
`* * *
`identify confidential
`rules
`Information: The
`Confidential
`information in a manner consistent with Federal Rule of Civil
`Procedure 26(c)(1)(G), which provides for protective orders for
`trade secret or other confidential research, development, or
`commercial information. § 42.54.
`
`
`The standard for granting a motion to seal is “for good cause.” 37 C.F.R. §
`
`42.54. Patent Owner, as the moving party, has the burden of proof in showing
`
`entitlement to the requested relief. Id.
`
`III. Good Cause Exists for Sealing Exhibits 2058-2060, 2069, 2074-2076,
`2078, 2080, 2082-2083, 2089-2090, 2092-2095, 2131, 2132, and 2138, and the
`Patent Owner Response.
`Exhibit 2132: Exhibit 2132 is the declaration of Dr. Brian Reisetter. Dr.
`
`
`
`Reisetter opines that the invention claimed in the challenged patent (U.S.
`
`9,815,827) has been commercially successful. In reaching his opinion, Dr.
`
`Reisetter relies upon and discusses sensitive financial and competitive commercial
`
`2
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`information from Patent Owner—in particular Exhibits 2069, 2074-2076, 2078,
`
`2080, 2082-2083, and 2089-2090.
`
`
`
`Exhibit 2069: Exhibit 2069 (Lurasidone, Strategic Business Plan, October
`
`1, 2009) contains sensitive financial and competitive commercial information
`
`relating to the anticipated commercial launch of LATUDA®.
`
`
`
`Exhibit 2074: Exhibit 2074 (Latuda Financial Information FY11-FY20
`
`YTD) contains sensitive financial information, including sales and pricing
`
`information, related to LATUDA®.
`
`
`
`Exhibit 2075: Exhibit 2075 (LATUDA Monthly Commercial Analytics
`
`Meeting, June 2016) contains sensitive financial and competitive commercial
`
`information related to LATUDA®.
`
`
`
`
`
`Exhibit 2076: Exhibit 2076 (LATUDA Situational Assessment – FY 2020,
`
`Aug 2, 2020) contains sensitive financial and competitive commercial information,
`
`as well as confidential business analyses related to LATUDA®.
`
`
`
`Exhibit 2078: Exhibit 2078 (Latuda® (lurasidone HCl) 2013 Brand Plan)
`
`contains sensitive financial and competitive commercial information relating to the
`
`2013 marketing plan for LATUDA®.
`
`
`
`Exhibit 2080: Exhibit 2080 (Latuda Physician ATU Tracker Findings,
`
`Q3’11 Insights Report) contains proprietary data and analysis related to the use of
`
`LATUDA® by physicians.
`
`3
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`Exhibit 2082: Exhibit 2083 (LATUDA – Bipolar Depression HCP ATU,
`
`
`
`FY16-Q4, March 20, 2017) contains proprietary data and analysis related to the
`
`use of LATUDA® for treating bipolar depression by physicians.
`
`
`
`Exhibit 2083: Exhibit 2083 (The Bipolar Disorder Patient Journey,
`
`Sunovion Commercial Insights & Analytics, INSYNC, June 22, 2020) includes
`
`proprietary competitive commercial analysis relating to LATUDA® and its use to
`
`treat bipolar disorder.
`
`
`
`Exhibit 2089: Exhibit 2089 (Sunovion Senior Leadership Budget
`
`Presentation, Latuda Brand Strategy and Budget, December 10, 2010) contains
`
`sensitive financial and competitive commercial information relating to the budget
`
`and marketing strategy for LATUDA®.
`
`
`
`Exhibit 2090: Exhibit 2090 (Latuda® 2012 Budget Presentation Meeting,
`
`November 7, 2011) contains sensitive financial and competitive commercial
`
`information relating to the proposed LATUDA® budget for 2012.
`
`
`
`Exhibit 2131: Exhibit 2131 is the declaration of Dr. Stephen Stahl. In the
`
`declaration, Dr. Stahl expresses his opinion that claims 1-75 of the challenged
`
`patent (U.S. 9,815,827) would not have been obvious. In forming his opinion, Dr.
`
`Stahl relied upon and discusses confidential documents containing proprietary data
`
`and confidential communications with FDA and third parties.
`
`4
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`Exhibits 2058, 2059, 2060: Exhibits 2058-2060 are confidential Clinical
`
`
`
`Study Reports submitted to FDA relating to LATUDA®. Each contains
`
`proprietary data related to various clinical studies.
`
`
`
`Exhibit 2092: Exhibit 2092 (Covance Cardiac Safety Services, Phase III
`
`Repolarization Assessment Plan, Lurasidone, Feb. 13, 2007) is a document
`
`describing a plan prepared by a third party at Patent Owner’s request to assess
`
`lurasidone. It contains proprietary scientific protocols and data.
`
`
`
`Exhibit 2093: Exhibit 2093 (Medifacts International, Review of the
`
`Preliminary Results from MK-3756 Protocol 023, February 7, 2007) describes the
`
`results of a study performed by a third party at Patent Owner’s request relating to
`
`lurasidone. It contains proprietary scientific protocols and data.
`
`
`
`Exhibit 2094: Exhibit 2094 (Clinical Pharmacology and Biopharmaceutics
`
`Review Aid, Dainippon Sumitomo Pharma America, Inc., Lurasidone) describes
`
`the results of a clinical study performed by Patent Owner. It contains proprietary
`
`scientific protocols and data.
`
`
`
`Exhibit 2095: Exhibit 2095 (Sunovion FDA Contact Report, Lurasidone
`
`HCl, October 25, 2010) describes proprietary communications between Patent
`
`Owner and FDA regarding lurasidone.
`
`5
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`Exhibit 2138: Exhibit 2138 (Memorandum With Respect to Lurasidone
`
`
`
`Development Handover Status (2007) describes a confidential agreement between
`
`Patent Owner and a third party relating to the development of lurasidone.
`
`
`
`Patent Owner Response: The Patent Owner Response includes portions
`
`that refer to and discuss the above-described exhibits.
`
`IV. Certification of Non-Publication
`
`On behalf of Patent Owner, undersigned counsel certifies the information
`
`sought to be sealed has not been published or otherwise made public. Further, the
`
`confidentiality of this information has been consistently maintained by the Patent
`
`Owner during this proceeding, and any related proceedings.
`
`V. Certification of Conference with Opposing Party Pursuant to 37 C.F.R.
`§42.54
`
`
`Patent Owner has conferred in good faith with Petitioner and has reached
`
`agreement as to the terms and the scope of the Proposed Protective Order.
`
`Specifically, Patent Owner and Petitioner have agreed to use the default protective
`
`order set forth in the Office Patent Trial Practice Guide to govern the handling of
`
`confidential information in this proceeding.
`
`VI. Proposed Protective Order
`
`The Protective Order attached hereto as Appendix A corresponds to the
`
`default protective order set forth in the Office Patent Trial Practice Guide. Patent
`
`Owner and Petitioner have agreed to use the attached protective order to govern the
`
`6
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`handling of confidential information in this proceeding. Per agreement of the
`
`parties, confidential information will be designated “IPR Protective Order
`
`Material.” Accordingly, Patent Owner respectfully requests entry of the Proposed
`
`Protective Order.
`
`VII. Confidential and Non-Confidential Versions
`
` Submitted herewith are non-confidential versions of the Patent Owner
`
`Response and Ex. 2131. Confidential versions are being filed concurrently.
`
`VIII. Conclusion
`
`For the above reasons, Patent Owner, Sumitomo Dainippon Pharma Co.,
`
`Ltd, respectfully requests Exhibits 2058-2060, 2069, 2074-2076, 2078, 2080,
`
`2082-2083, 2089-2090, 2092-2095, 2132, and 2138, and the unredacted versions
`
`of Ex. 2131 and the Patent Owner Response, to be treated as confidential
`
`information and be placed under seal.
`
`
`
`
`
`
`Date: March 11, 2021
`
`
`Fish & Richardson P.C.
`Telephone: (612) 335-5070
`Facsimile: (877) 769-7945
`
`
` Respectfully submitted,
`
` /Dorothy P. Whelan/
` Dorothy P. Whelan
` Reg. No. 33,814
`
`
`
`7
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 CFR §§ 42.6(e)(4), the undersigned certifies that on March
`
`11, 2021, a complete and entire copy of this Patent Owner’s Motion to Seal was
`
`provided by email to the Petitioner by serving the correspondence email addresses
`
`of record as follows:
`
`
`
`Louis H. Weinstein
`Patrick G. Pollard
`Windels Marx Lane & Mittendorf, LLP
`1 Giralda Farms
`Madison, NJ 07940
`
`Email: lweinstein@windelsmarx.com
`ppollard@windelsmarx.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Diana Bradley/
`
`Diana Bradley
`Fish & Richardson P.C.
`3200 RBC Plaza
`60 South Sixth Street
`Minneapolis, MN 55402
`(858) 678-5667
`
`
`
`
`
`
`
`
`
`
`
`8
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`APPENDIX A
`
`
`9
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`
`SLAYBACK PHARMA LLC,
`Petitioners
`
`v.
`
`SUMITOMO DAINIPPON PHARMA CO., LTD.,
`Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2020-01053
`Patent No. 9,815,827
`
`
`
`
`
`
`
`
`
`
`
`
`PROTECTIVE ORDER
`
`This standing protective order governs the treatment and filing of
`
`confidential information, including documents and testimony.
`
`1. Confidential information shall be clearly marked ‘‘IPR PROTECTIVE
`
`ORDER MATERIAL.’’
`
`10
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`2. Access to confidential information is limited to the following individuals
`
`who have executed the acknowledgment appended to this order:
`
`(A) Parties. Persons who are owners of a patent involved in the proceeding
`
`and other persons who are named parties to the proceeding.
`
`(B) Party Representatives. Representatives of record for a party in the
`
`proceeding.
`
`(C) Experts. Retained experts of a party in the proceeding who further
`
`certify in the Acknowledgement that they are not a competitor to any party, or a
`
`consultant for, or employed by, such a competitor with respect to the subject matter
`
`of the proceeding.
`
`(D) In-house counsel. In-house counsel of a party.
`
`(E) Other Employees of a Party. Employees, consultants or other persons
`
`performing work for a party, other than in-house counsel and in-house counsel’s
`
`support staff, who sign the Acknowledgement shall be extended access to
`
`confidential information only upon agreement of the parties or by order of the
`
`Board upon a motion brought by the party seeking to disclose confidential
`
`information to that person. The party opposing disclosure to that person shall have
`
`the burden of proving that such person should be restricted from access to
`
`confidential information.
`
`11
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`(F) The Office. Employees and representatives of the Office who have a need
`
`for access to the confidential information shall have such access without the
`
`requirement to sign an Acknowledgement. Such employees and representatives
`
`shall include the Director, members of the Board and their clerical staff, other
`
`support personnel, court reporters, and other persons acting on behalf of the Office.
`
`(G) Support Personnel. Administrative assistants, clerical staff, court
`
`reporters and other support personnel of the foregoing persons who are reasonably
`
`necessary to assist those persons in the proceeding shall not be required to sign an
`
`Acknowledgement, but shall be informed of the terms and requirements of the
`
`Protective Order by the person they are supporting who receives confidential
`
`information.
`
`3. Persons receiving confidential information shall use reasonable efforts to
`
`maintain the confidentiality of the information, including:
`
`(A) Maintaining such information in a secure location to which persons not
`
`authorized to receive the information shall not have access;
`
`(B) Otherwise using reasonable efforts to maintain the confidentiality of the
`
`information, which efforts shall be no less rigorous than those the recipient uses to
`
`maintain the confidentiality of information not received from the disclosing party;
`
`12
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`(C) Ensuring that support personnel of the recipient who have access to the
`
`confidential information understand and abide by the obligation to maintain the
`
`confidentiality of information received that is designated as confidential; and
`
`(D) Limiting the copying of confidential information to a reasonable number
`
`of copies needed for conduct of the proceeding and maintaining a record of the
`
`locations of such copies.
`
`4. Persons receiving confidential information shall use the following
`
`procedures to maintain the confidentiality of the information:
`
`(A) Documents and Information Filed With the Board.
`
`(i) A party may file documents or information with the Board under seal,
`
`together with a non-confidential description of the nature of the confidential
`
`information that is under seal and the reasons why the information is confidential
`
`and should not be made available to the public. The submission shall be treated as
`
`confidential and remain under seal, unless, upon motion of a party and after a
`
`hearing on the issue, or sua sponte, the Board determines that the documents or
`
`information do not to qualify for confidential treatment.
`
`(ii) Where confidentiality is alleged as to some but not all of the information
`
`submitted to the Board, the submitting party shall file confidential and non-
`
`confidential versions of its submission, together with a Motion to Seal the
`
`confidential version setting forth the reasons why the information redacted from
`
`13
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`the non-confidential version is confidential and should not be made available to the
`
`public. The nonconfidential version of the submission shall clearly indicate the
`
`locations of information that has been redacted. The confidential version of the
`
`submission shall be filed under seal. The redacted information shall remain under
`
`seal unless, upon motion of a party and after a hearing on the issue, or sua sponte,
`
`the Board determines that some or all of the redacted information does not qualify
`
`for confidential treatment.
`
`(B) Documents and Information Exchanged Among the Parties. Information
`
`designated as confidential that is disclosed to another party during discovery or
`
`other proceedings before the Board shall be clearly marked as “IPR PROTECTIVE
`
`ORDER MATERIAL” and shall be produced in a manner that maintains its
`
`confidentiality.
`
`(j) Standard Acknowledgement of Protective Order. The following form may
`
`be used to acknowledge a protective order and gain access to information covered
`
`by the protective order:
`
`14
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`
`SLAYBACK PHARMA LLC,
`Petitioners
`
`v.
`
`SUMITOMO DAINIPPON PHARMA CO., LTD.,
`Patent Owner
`
`
`
`Standard Acknowledgment for Access to
`Protective Order Material
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2020-01053
`Patent No. 9,815,827
`
`
`
`
`
`
`
`
`
`
` I
`
` _____________________________, affirm that I have read the Protective
`
`Order; that I will abide by its terms; that I will use the confidential information
`
`only in connection with this proceeding and for no other purpose; that I will only
`
`allow access to support staff who are reasonably necessary to assist me in this
`
`15
`
`
`
`
`
`Attorney Docket No.: 46094-0002IP1
`Case No.: IPR2020-01053
`proceeding; that prior to any disclosure to such support staff I informed or will
`
`inform them of the requirements of the Protective Order; that I am personally
`
`responsible for the requirements of the terms of the Protective Order and I agree to
`
`submit to the jurisdiction of the Office and the United States District Court for the
`
`Eastern District of Virginia for purposes of enforcing the terms of the Protective
`
`Order and providing remedies for its breach.
`
`
`
`Signed ____________________________________________
`
`
`
`
`
`16
`
`
`
`